EGFR and non-small cell lung carcinoma: While the interaction effect of the pathological stage and 3 groups according to EGFR and ALK variation (EGFR variation–positive, ALK-positive, or EGFR and ALK wild type NSCLC) was significant, pathological stage was associated with risk of recurrence (adjusted hazard ratio, 3.92; 95% CI, 3.17-4.84 for stage II vs I; 6.07; 95% CI, 4.86-7.59 for stage IIIA vs I; all P < .001) (eFigure 2 in Supplement 1).